What is Oppenheimer's price target for RXDX?

Oppenheimer's latest stated price target for Prometheus Biosciences Inc. (RXDX) is $50, from its action on Dec 8, 2021.

What is Oppenheimer's rating on RXDX?

Oppenheimer rates RXDX Outperform, a bullish rating, as of Dec 8, 2021.

When did Oppenheimer last change its view on RXDX?

On Dec 8, 2021, Oppenheimer upgrades to Outperform from Perform, price target $35 to $50.

Oppenheimer RXDX price target and rating history

Prometheus Biosciences Inc. (RXDX) · Health Care

Oppenheimer rates Prometheus Biosciences Inc. (RXDX) Outperform with a $50 price target, as of its latest action on Dec 8, 2021. It has published 4 rating actions on RXDX since October 2021, including 1 upgrade and 2 downgrades.

Current rating: Outperform
Price target: $50
Median target, all firms: Too few
Actions on RXDX: 4

Oppenheimer price target on RXDX

Oppenheimer price target on RXDX, each point a stated target, October 2021 to December 2021.

Every Oppenheimer rating on RXDX

Dec 8, 2021
UpgradeOppenheimer upgrades to Outperform from Perform, price target $35 to $50
Nov 15, 2021
DowngradeOppenheimer downgrades to Perform from Outperform, price target $35
Nov 15, 2021
DowngradeOppenheimer downgrades to Perform from Outperform
Oct 5, 2021
InitiateOppenheimer starts coverage at Outperform, price target $35

Questions about Oppenheimer and RXDX

What is Oppenheimer's price target for RXDX?: Oppenheimer's latest stated price target for Prometheus Biosciences Inc. (RXDX) is $50, from its action on Dec 8, 2021.
What is Oppenheimer's rating on RXDX?: Oppenheimer rates RXDX Outperform, a bullish rating, as of Dec 8, 2021.
When did Oppenheimer last change its view on RXDX?: On Dec 8, 2021, Oppenheimer upgrades to Outperform from Perform, price target $35 to $50.

More RXDX rating histories

Leerink Partners3

All Oppenheimer ratings RXDX news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.